GlassScriptPhysician profile
Kelli A Rice
NPI 1881144376
$114,208.41
in general payments reported to CMS, 2019-2025
7 companies · $42K in 2025
The $42K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $8,904 · 2023: $24K · 2024: $39K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Travel and Lodging: $19K · Consulting Fee: $8,949 · Food and Beverage: $7,053 · Honoraria: $4,300 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $686 · Education: $12.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,129.00 |
| Travel and Lodging | $19,175.15 |
| Consulting Fee | $8,949.17 |
| Food and Beverage | $7,052.84 |
| Honoraria | $4,300.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $685.76 |
| Education | $12.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $54,952.55 | 2023-2025 | |
| Ucb, INC. | $25,662.95 | 2023-2025 | Briviact, Nayzilam, Fintepla |
| Livanova USA, INC. | $15,546.55 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Sk Life Science, INC. | $15,306.77 | 2022-2025 | Xcopri |
| Abbvie INC. | $2,495.72 | 2023 | |
| Stability Biologics, LLC | $225.62 | 2023 | |
| Neurelis, INC. | $18.25 | 2024 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.